Euro International Meet on Biotechnology and Biomedical Engineering

Biography

Biography

Biography

Biography

Biography

Biography

Biography

Biography

Biography

Thomas J. Webster’s (H index: 139) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has formed over a dozen companies who have numerous FDA approved medical products currently improving human health in over 45,000 patients. He is currently helping those companies and serves as a professor at Brown University, Saveetha University, Hebei University of Technology, UFPI, University of the Basque Country, and others. Dr. Webster has numerous awards including: 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Materials Science and Mixed Fields); 2021, Clarivate Top 0.1% Most Influential Researchers (Pharmacology and Toxicology); 2022, Best Materials Science Scientist by Citations (Research.com); and is a fellow of over 8 societies. Prof. Webster is a former President of the U.S. Society for Biomaterials and has over 1,350 publications to his credit with over 55,000 citations. He was recently nominated for the Nobel Prize in Chemistry. Prof. Webster also recently formed a fund to support Nigerian student research opportunities in the U.S.

Research

Biography

Dr. Bernd Blobel studied Mathematics, Technical Cybernetics and Electronics, Bio-Cybernetics, Physics, Medicine and Informatics at the University of Magdeburg and other universities in the former GDR. He received his PhD in Physics with a neurophysiological study. Furthermore, he performed the Habilitation (qualification as university professor) in Medicine and Informatics. He was Head of the Institute for Biometrics and Medical Informatics at the University of Magdeburg, and thereafter Head of the Health Telematics Project Group at the Fraunhofer IIS in Erlangen. Thereafter, he acted until his retirement as Head of the German National eHealth Competence Center as well as Head of the globally unique International Interdisciplinary PhD and PostDoc College at the University of Regensburg. He is also Visiting Professor at the Charles University in Prague. He was and is still leadingly involved in many countries health digitalization as well as electronic health record strategy. He published more than 600 papers, published/edited many books and supervised a big number of PhD students from all around the world. He was German Representative to many SDOs such as HL7, ISO, CEN, OMG, IEEE, ASTM, SNOMED, etc., also chairing the national mirror groups. Furthermore, he still engaged in international higher education. He is Fellow of several international academies and played specific roles in global organizations such as WHO, European Commission, UNESCO, etc.

Research

Biography

Brian Blagg is the Charles Huisking Professor of Chemistry and Biochemistry and Director of the Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame. After earning a B.A. in Chemistry and Environmental Studies at Sonoma State University, and his Ph.D. in Organic Chemistry from the University of Utah (Dale Poulter), he received an NIH Postdoctoral Fellowship and performed research at The Scripps Research Institute with Dale Boger. Blagg started his independent career in medicinal chemistry at The University of Kansas is 2002. In the Fall of 2017, he moved to The University of Notre Dame wherein his lab continues to focus on chaperone proteins and protein folding in relation to cancer and neurodegeneration. Cancers are inherently more dependent on chaperone proteins because of their constant division and cellular stress. Consequently, Blagg’s team works to selectively inhibit chaperone proteins to halt cancer growth. In contrast, his lab also studies the potential for utilizing chaperones to re-fold malfunctioning and/or aggregated proteins for the treatment of Alzheimer’s disease and glaucoma. Brian Blagg is married to Leah Blagg and has three children, ranging in ages from 14 and 27. When not thinking about science, he can be found with his family and friends.

Brian Blagg has produced more than 333 publications/ patents and was formerly an Associate/Senior Editor of The Journal of Medicinal Chemistry. He is also an inventor of KU-596 (cemdomespid) a drug currently undergoing phase II clinical trials for the treatment of neuropathy via Biogen/Reata Therapeutics. Blagg is also a founder of Grannus Therapeutics, which plans to introduce a new oncology drug into trails in 2026.

Research